Kosmidou 2008.

Methods	6‐Week dietary lead‐in 12‐Week before‐and‐after study
Participants	97 men and women with hyperlipidaemia with and without HTN; LDL‐C > 160 mg/dL (4.14 mmol/L), TG < 250 mg/dL (2.82 mmol/L) 60 participants received atorvastatin, 37 received no medication Exclusion criteria: renal dysfunction, liver disease, TSH > 5 mU/L, diabetes mellitus, childbearing potential, use of lipid‐altering drugs, antihypertensive therapy Atorvastatin baseline TC: 7.3 mmol/L (282 mg/dL) Atorvastatin baseline LDL‐C: 5.1 mmol/L (197 mg/dL) Atorvastatin baseline HDL‐C: 1.3 mmol/L (50 mg/dL) Atorvastatin baseline TG: 1.9 mmol/L (168 mg/dL)
Interventions	Atorvastatin 20 mg/d
Outcomes	Per cent change from baseline at 12 weeks of serum TC, LDL‐C, HDL‐C and TG
Notes	SDs were imputed
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Atorvastatin 20 mg/d; intervention was analysed, and as no placebo group was included for comparison, assessment of random sequence generation is not applicable
Allocation concealment (selection bias)	Unclear risk	Atorvastatin 20 mg/d; intervention was analysed, and as no placebo group was included for comparison, assessment of allocation concealment is not applicable
Blinding (performance bias and detection bias) All outcomes	Unclear risk	Atorvastatin 20 mg/d; intervention was analysed, and as no placebo group was included for comparison, blinding status is not applicable
Incomplete outcome data (attrition bias) All outcomes	Low risk	Data on all participants were reported
Selective reporting (reporting bias)	Low risk	All lipid parameters were measured
Other bias	Unclear risk	The source of funding was not provided